Tokyo (JCNN) - Chugai Pharmaceutical (TSE: 4519) has announced that it has received approval for expanded indications of
Natulan, an antitumor agent, from the Ministry of Health, Labor and Welfare (Japan).
The newly approved agent is now applicable to the treatment of glioma with malignant astrocytoma and oligodendroglioma.
Developed by F. Hoffmann-La Roche, Natulan, a methylhydrazine compound, has been used in the treatment of malignant lymphoma
since 1977.
View Chugai Pharmaceutical Co., Ltd. company
profile here
Copyright © 2001-2004 JCNN. All rights reserved. A
division of Japan Corporate News Network KK.